LRRC18 Inhibitors
LRRC18 inhibitors encompass a category of chemical compounds specifically designed to target and impede the function of the LRRC18 protein, a member of the leucine-rich repeat-containing protein family. These inhibitors function by interacting with the LRRC18 protein at a molecular level, effectively obstructing its normal biological activities. The mode of action of these inhibitors is characterized by their ability to bind to the active or allosteric sites on the LRRC18 protein, which can result in the alteration of protein conformation, the prevention of substrate binding, or the disruption of protein-protein interactions that are essential for the normal function of LRRC18. Due to the specificity of LRRC18 inhibitors, they are able to selectively target the pathways in which LRRC18 is a critical component, thereby providing a focused approach to modulating the biological processes governed by this protein. The development of these inhibitors is founded on insights into the structure-function relationship of LRRC18, enabling the fine-tuning of inhibitor design for greater potency and selectivity.
The chemical compounds classified as LRRC18 inhibitors are diverse in structure, yet they share the common goal of mitigating the activity of the LRRC18 protein. These inhibitors typically work by either directly binding to LRRC18, leading to a reduction in its activity, or by influencing the signaling pathways that regulate the expression or activity of LRRC18. The biochemical pathways affected by LRRC18 and its inhibitors often involve complex signaling cascades where the inhibition of LRRC18 activity can have downstream effects on cellular processes. By curtailing the activity of LRRC18, these inhibitors effectively alter the cellular dynamics that rely on the proper functioning of this protein. The specificity and precision of LRRC18 inhibitors make them valuable tools in research settings, providing a means to dissect and understand the role of LRRC18 in various biological contexts. While the primary focus of these compounds is to elucidate the biological mechanisms in which LRRC18 participates, their high specificity also contributes to the understanding of the intricate networks that maintain cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR (mammalian target of rapamycin), which can lead to a decrease in LRRC18 activity by reducing cellular proliferation signals that would otherwise increase the expression and functionality of LRRC18. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it may reduce the downstream signaling that could involve the regulation of LRRC18 as a response to stress or inflammation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Inhibition of the PI3K/Akt pathway can lead to reduced transcriptional activity for a range of proteins, potentially including LRRC18, by affecting the stability and expression levels of the proteins involved in this signaling cascade. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor which blocks the MAPK/ERK pathway. This pathway often regulates gene expression and protein synthesis; thus, inhibition may result in decreased LRRC18 levels or activity by preventing necessary post-translational modifications. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor which may interfere with the JNK signaling pathway. This pathway is implicated in various stress responses and its inhibition could affect the transcriptional regulation mechanisms wherein LRRC18 may be involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor like LY294002, and its effects on the PI3K/Akt pathway can similarly lead to a decrease in LRRC18 expression or stability by altering the cellular growth and survival signals that may indirectly affect LRRC18. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, which can reduce angiogenesis and cell proliferation signals. This could indirectly influence the regulation of LRRC18 by reducing the signals that may upregulate its activation or expression. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor and by inhibiting Rho-associated, coiled-coil containing protein kinase, it can modify the actin cytoskeleton dynamics. This alteration can affect cellular mechanisms that potentially regulate the expression or activity of LRRC18. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor, which could lead to a decrease in LRRC18 activity by inhibiting the EGFR signaling pathway, known to be involved in cell survival and proliferation, and potentially affecting the expression or stability of LRRC18. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor targeting both EGFR and HER2/neu, which can inhibit the cell proliferation signaling pathway and may result in decreased LRRC18 expression or activity by influencing pathways that regulate its expression. | ||||||